TG Therapeutics, currently priced around US$34.30, has shown mixed stock performance with an annual decline of 10.5% while gaining 17.1% year-to-date. Recent analysis indicates the stock may be undervalued, with a discounted cash flow (DCF) model suggesting an intrinsic value of approximately US$110.95 per share—indicating a 69.1% discount at its current price. Additionally, its P/E ratio of 11.33x is below industry averages, further signaling potential undervaluation. Two different narratives for future earnings suggest a bull case fair value of US$44.43 and a bear case of US$17.32, highlighting the wide range of investor sentiment regarding TG Therapeutics’ growth prospects, particularly centered on its flagship product, BRIUMVI.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tgtx/tg-therapeutics/news/has-the-market-mispriced-tg-therapeutics-tgtx-after-recent-b
